CardiaTec

ABOUT

CardiaTec offers validated drug candidates for the treatment of Coronary Artery Disease/Acute Coronary Syndrome (CAD/ACS). CardiaTec’s proprietary ML architecture integrates information from scientific literature, structured databases and proprietary dataset derived from ACS-specific multi-omic analysis to generate drug targets. Pharma and biotech customers use these targets to develop novel therapeutics or repurpose drugs. 

FOUNDERS

Dr. Namshik Han, Raphael Peralta, Thelma Zablocki

CO-INVESTORS

Laidlaw Scholars Ventures, O2H Ventures, Cambridge Enterprise

INDUSTRY

AI, Multi-Omics, Drug Development

FOLLOW CARDIATEC